HUE061482T2 - Szintézismódszer - Google Patents

Szintézismódszer

Info

Publication number
HUE061482T2
HUE061482T2 HUE20816375A HUE20816375A HUE061482T2 HU E061482 T2 HUE061482 T2 HU E061482T2 HU E20816375 A HUE20816375 A HU E20816375A HU E20816375 A HUE20816375 A HU E20816375A HU E061482 T2 HUE061482 T2 HU E061482T2
Authority
HU
Hungary
Prior art keywords
synthesis
Prior art date
Application number
HUE20816375A
Other languages
English (en)
Inventor
Peter Rands
George Knight
Richard Chubb
Derek Londesbrough
Tiffanie Benway
Zelah Joel
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1916210.6A external-priority patent/GB201916210D0/en
Priority claimed from GBGB1917320.2A external-priority patent/GB201917320D0/en
Priority claimed from GB2008303.6A external-priority patent/GB2585978B/en
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Publication of HUE061482T2 publication Critical patent/HUE061482T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
HUE20816375A 2019-11-07 2020-11-09 Szintézismódszer HUE061482T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1916210.6A GB201916210D0 (en) 2019-11-07 2019-11-07 High purity tryptamines and methods of synthesis thereof
GBGB1917320.2A GB201917320D0 (en) 2019-11-28 2019-11-28 Novel compounds
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions

Publications (1)

Publication Number Publication Date
HUE061482T2 true HUE061482T2 (hu) 2023-07-28

Family

ID=75849570

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE20816376A HUE059403T2 (hu) 2019-11-07 2020-11-09 Vegyületek
HUE20816375A HUE061482T2 (hu) 2019-11-07 2020-11-09 Szintézismódszer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE20816376A HUE059403T2 (hu) 2019-11-07 2020-11-09 Vegyületek

Country Status (18)

Country Link
US (4) US11643390B2 (hu)
EP (3) EP3873883B1 (hu)
JP (3) JP7423131B2 (hu)
KR (2) KR20230142817A (hu)
CN (2) CN114829341B (hu)
AU (2) AU2020381103B2 (hu)
BR (1) BR112022008919A2 (hu)
CA (2) CA3160334A1 (hu)
DK (1) DK3844147T3 (hu)
ES (2) ES2940811T3 (hu)
HR (2) HRP20220797T1 (hu)
HU (2) HUE059403T2 (hu)
IL (2) IL292753B2 (hu)
MX (1) MX2022005399A (hu)
NZ (1) NZ788543A (hu)
PL (2) PL3844147T3 (hu)
PT (2) PT3844147T (hu)
WO (2) WO2021089873A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HUE059403T2 (hu) 2019-11-07 2022-11-28 Small Pharma Ltd Vegyületek
CN115974757A (zh) 2020-02-04 2023-04-18 明德赛特制药公司 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物
US11332441B2 (en) * 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
MX2022014900A (es) * 2020-06-02 2023-03-27 Small Pharma Ltd Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada.
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
WO2021250434A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4122916A1 (en) * 2021-07-22 2023-01-25 GH Research Ireland Limited Method for preparing an organic compound
CA3226980A1 (en) * 2021-07-22 2023-01-26 GH Research Ireland Limited Method for preparing a tryptamine derivative.
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
WO2023089132A1 (en) 2021-11-18 2023-05-25 Small Pharma Ltd Injectable and inhalable formulations
WO2023108174A1 (en) * 2021-12-10 2023-06-15 Terran Biosciences, Inc. Analogs of 6-methoxy- n, n-dimethyltryptamine
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
US20240101514A1 (en) * 2022-08-19 2024-03-28 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
WO2024079314A1 (en) 2022-10-13 2024-04-18 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336378A (en) 1980-04-10 1982-06-22 Sandoz, Inc. Isoxazolyl indolamines
JPH06508354A (ja) * 1991-06-21 1994-09-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー トリプタミン類似体、その合成法およびその5−ht↓1様または5−ht↓2受容体作用物質としての使用
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
AU2001266896B2 (en) 2000-06-16 2006-04-06 Jagotec Ag Improved injectable dispersions of propofol
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
CN101687788A (zh) 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
CZ302424B6 (cs) * 2007-06-13 2011-05-11 Zentiva, A. S. Zpusob prípravy almotriptanu o vysoké cistote
NZ583192A (en) * 2007-08-06 2012-06-29 Biotie Therapies Inc Methods for treating dependence
US20090076121A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
WO2009049030A1 (en) 2007-10-09 2009-04-16 Triton Biopharma, Llc Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
KR102232221B1 (ko) * 2013-03-14 2021-03-26 다트 뉴로사이언스 (케이만) 엘티디. Pde4 억제제로서 치환된 피리딘 및 피라진 화합물
WO2016181414A1 (en) 2015-05-12 2016-11-17 Council Of Scientific & Industrial Research Process for the synthesis of ivacaftor and related compounds
US20200030309A1 (en) * 2016-09-29 2020-01-30 The Regents Of The University Of California Compounds for increasing neural plasticity
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019081764A1 (en) 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases
EA202192318A1 (ru) 2019-02-22 2021-12-21 Гх Рисерч Айрленд Лимитед 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии
JP2022522659A (ja) 2019-02-22 2022-04-20 ジーエイチ リサーチ アイルランド リミテッド 精神障害の処置における使用のための5-メトキシ-n,n-ジメチルトリプタミン(5-meo-dmt)を含む組成物
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
CA3130767A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HUE059403T2 (hu) 2019-11-07 2022-11-28 Small Pharma Ltd Vegyületek
CN111072492A (zh) * 2019-11-29 2020-04-28 浙江工业大学 一种合成3,4-二氯-2-氨基-5-氟联苯的方法
CN115974757A (zh) 2020-02-04 2023-04-18 明德赛特制药公司 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
BR112023001967A2 (pt) 2020-08-05 2023-02-28 Univ Basel Método para induzir um estado psicodélico em um indivíduo, método para induzir um estado psicodélico em um indivíduo com segurança, método para fornecer um tratamento psicodélico de curta duração, método para determinar uma dose de dmt para um indivíduo, método para terapia e método para ajustar um estado psicodélico em um indivíduo em tempo real
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
CN115701994B (zh) 2020-08-28 2024-03-08 赛本英国有限公司 可注射制剂
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
CA3194558A1 (en) 2020-10-02 2022-04-07 Brett J. GREENE Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Also Published As

Publication number Publication date
PL3873883T3 (pl) 2023-05-08
EP3873883A1 (en) 2021-09-08
AU2020381103A1 (en) 2022-06-09
PT3844147T (pt) 2022-07-04
NZ788543A (en) 2022-10-28
JP2024028798A (ja) 2024-03-05
JP7423131B2 (ja) 2024-01-29
EP4180037A1 (en) 2023-05-17
CN114829341A (zh) 2022-07-29
MX2022005399A (es) 2022-07-05
CN114829341B (zh) 2024-03-08
PL3844147T3 (pl) 2022-07-18
IL292753A (en) 2022-07-01
IL292754A (en) 2022-07-01
AU2020378647B2 (en) 2023-06-15
JP2022546635A (ja) 2022-11-04
BR112022008919A2 (pt) 2022-08-09
PT3873883T (pt) 2023-03-24
KR20230142817A (ko) 2023-10-11
CA3160337C (en) 2023-08-29
US20210395201A1 (en) 2021-12-23
EP3873883B1 (en) 2022-12-21
US11643390B2 (en) 2023-05-09
CN114829340B (zh) 2023-12-12
AU2020381103B2 (en) 2022-08-11
JP2023500532A (ja) 2023-01-06
AU2020378647A1 (en) 2022-06-09
CA3160334A1 (en) 2021-05-14
JP7422473B2 (ja) 2024-01-26
WO2021089873A1 (en) 2021-05-14
US20230167056A1 (en) 2023-06-01
CN114829340A (zh) 2022-07-29
IL292753B2 (en) 2024-01-01
DK3844147T3 (da) 2022-07-04
HRP20220797T1 (hr) 2022-10-14
CA3160337A1 (en) 2021-05-14
IL292753B1 (en) 2023-09-01
ES2920681T3 (es) 2022-08-08
US20220281818A1 (en) 2022-09-08
KR20220082092A (ko) 2022-06-16
HUE059403T2 (hu) 2022-11-28
EP3844147A1 (en) 2021-07-07
ES2940811T3 (es) 2023-05-11
EP3844147B1 (en) 2022-04-06
US20230250059A1 (en) 2023-08-10
HRP20230281T1 (hr) 2023-04-28
US11578039B2 (en) 2023-02-14
WO2021089872A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
IL292754A (en) method of synthesis
IL271938A (en) A method for making synthesis gas
IL271939A (en) A method for making synthesis gas
IL271941A (en) A method for making synthesis gas
EP3712130A4 (en) METHOD OF SYNTHESIS OF ROXADUSTATE AND INTERMEDIATE COMPOUNDS THEREOF
ZA201908158B (en) Novel method for synthesizing amanitins
EP3611171A4 (en) METHOD OF SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF
GB201801768D0 (en) Synthesis method
GB201701396D0 (en) Novel alternating-phase synthesis method
GB201804594D0 (en) Bonegraft substituteand method of manufacture
ZA202101837B (en) Method for the preparation of synthesis gas
IL292210A (en) An efficient process for the synthesis of 2-amino-5-chloro-n,3-dimethylbenzamide
GB201802839D0 (en) Method of manufacture
IL291221A (en) Methods for the synthesis of wolbenzine
GB201903056D0 (en) Method of oligonucleotide synthesis
PL3755681T3 (pl) Sposób wytwarzania 4-boronofenyloalaniny
GB201903055D0 (en) Method of oligonucleaotide synthesis
PL3498665T3 (pl) Sposób otrzymywania gazu syntezowego
PT3759082T (pt) Processo para a síntese de 6-clorometiluracilo
EP3792296C0 (en) PROCESS FOR THE SYNTHESIS OF POLYETHERS
GB201804905D0 (en) Cataltic synthesis of biarylic compounds
GB201917499D0 (en) Methods of synthesis
GB201809404D0 (en) Method of synthesis
GB201807468D0 (en) Methods of synthesis
GB202017799D0 (en) Method of synthesis